ViroGates A/S

Copenhagen Stock Exchange VIRO.CO

ViroGates A/S Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD 2.71 M

ViroGates A/S Net Cash Used Provided By Financing Activities is USD 2.71 M for the year ending December 31, 2023, a 102.96% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

ViroGates A/S Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD 1.34 M, a 214.81% change year over year.
ViroGates A/S Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD 424.28 K, a -66.94% change year over year.
ViroGates A/S Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD 1.28 M, a 0.00% change year over year.
ViroGates A/S Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD 0.00, a -100.00% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

Copenhagen Stock Exchange: VIRO.CO

ViroGates A/S

CEO	Mr. Jakob Knudsen
IPO Date	June 26, 2018
Location	Denmark
Headquarters	BanevAenget 13
Employees	10
Sector	Healthcare
Industries Biotechnology Clinical Trials Drugstores & Retail Pharmacies Insurance Medical Instruments Pharmaceuticals Plastics Telehealth

Description

ViroGates A/S develops and markets prognostic products for the healthcare sector. It offers suPARnostic, a blood test that measures the soluble urokinase plasminogen activator receptor (suPAR) protein in the bloodstream used for emergency departments in hospitals to improve clinical decisions on hospitalization or discharge of acute medical patients and reduce healthcare cost. The company also provides suPARnostic TurbiLatex, a latex particle-enhanced turbidimetric immunoassay that quantitatively determines the suPAR level in human K2-EDTA- or lithium heparin plasma samples; suPARnostic Quick Triage kit, which is used in the point of care situation for early warning and patient triaging; and suPARnostic ELISA that provides fully quantitative results. Its suPAR prognostic tool used in various diseases, such as cardiovascular, kidney, cancer, diabetes, liver, infectious, respiratory, and rheumatic. The company was incorporated in 2000 and is headquartered in Birkerød, Denmark.

Key trends

Past 5 years